Treating subjects having a
lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from
lipid storage disorders, such as Niemann-Pick
disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C
disease a pharmaceutically effective amount of bryostatin 1.